Author/Authors :
Mollazadeh-Moghaddam، Kamyar نويسنده Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.National Drug and Poison Information Center, Deputy of Food , , Jamali، Arsia نويسنده Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Milad Clinical Research Center, Milad Hospital, Tehran, Ira , , Adili-Aghdam، Fatemeh نويسنده Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran , , Akhondzadeh، Shahin نويسنده ,
Abstract :
Donepezil, a member of the acetylcholinesterase inhibitor family, is approved for management of cognitive impairments as well as behavioral complications in patients with neurodegenerative Alzheimerʹs disease. Generally, donepezil is regarded as a safe medication in patients with Alzheimer’s disease although there have been reports of several minor adverse events including gastrointestinal disturbances. Herein we describe a patient with Alzheimer’s disease who demonstrated delirious behavior upon treatment with donepezil.
